Skip to Content
Learn about Adcetris a treatment of Hodgkin Lymphoma

Drug interactions between ACAM2000 and emapalumab

Results for the following 2 drugs:
ACAM2000 (smallpox vaccine)
emapalumab

Interactions between your drugs

Major

smallpox vaccine emapalumab

Applies to: ACAM2000 (smallpox vaccine) and emapalumab

Consumer information for this interaction is not currently available.

GENERALLY AVOID: The administration of live or live attenuated vaccines during emapalumab therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Emapalumab is a monoclonal antibody that binds to and neutralizes interferon gamma, which may increase susceptibility to certain pathogens and increase the risk of fatal and serious infections. In clinical trials, serious infections such as sepsis, pneumonia, bacteremia, disseminated histoplasmosis, necrotizing fasciitis, viral infections, and perforated appendicitis were observed in 32% of patients receiving emapalumab. The reported infections were 41% viral, 35% bacterial, 9% fungal, while in 15% of cases the pathogen was not identified. The safety of immunization with live vaccines during or following emapalumab therapy has not been studied.

MANAGEMENT: The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.

References

  1. "Product Information. Gamifant (emapalumab)." Sobi Inc, Ardmore, PA.

Drug and food interactions

No results found in our database - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide